European Commission Approves Dupilumab for Severe Asthma
The European Commission (EC) has approved dupilumab (Dupixent) as add-on maintenance therapy for patients 12 years or older with severe asthma with type 2 inflammation characterized by increased blood eosinophil levels and/or increased fractional exhaled nitric oxide, whose condition is poorly controlled with high-dose inhaled corticosteroid plus another medicine.The move follows a recommendation for approval by the European Medicines Agencys Committee for Medicinal P
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies